Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy

Abstract

Background/Objective : The rising global burden of cancer underscores the need for innovative therapies that address limitations of conventional treatments, such as drug resistance, systemic toxicity, and poor bioavailability. Plant-derived nanocarriers (PDNs) offer a sustainable, biocompatible, and effective platform for targeted drug delivery. This review explores the classifications, mechanisms, and therapeutic potential of PDNs in enhancing cancer treatment outcomes. Method : A comprehensive literature review was conducted using databases including Scopus, Web of Science, and PubMed, focusing on peer-reviewed publications from the past decade. Various PDN types such as phytosomes, lipid-based nanoparticles, polymeric nanoparticles, and exosome-like nanovesicles were examined. Mechanisms of drug encapsulation, release, and tumor targeting were analyzed alongside relevant preclinical and clinical case studies. Results : PDNs improve drug stability, solubility, and targeted delivery, minimizing toxicity to healthy tissues. Case studies highlight successful delivery of agents like curcumin, doxorubicin, and plant-derived alkaloids. Key challenges include scalability, stability, and regulatory hurdles. Emerging solutions such as green synthesis and integration with artificial intelligence are discussed. Conclusion : PDNs represent a promising frontier in cancer therapy by merging nanotechnology with natural biomaterials to enhance efficacy and personalization while reducing side effects. Overcoming current limitations could accelerate clinical adoption and revolutionize cancer treatment.